e-learning
resources
ERJ
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Therapeutic effects of nintedanib are not influenced by emphysema in the INPULSIS trials
Vincent Cottin, Arata Azuma, Ganesh Raghu, Wibke Stansen, Susanne Stowasser, Rozsa Schlenker-Herceg, Martin Kolb
Source:
Eur Respir J, 53 (4) 1801655; 10.1183/13993003.01655-2018
Journal Issue:
April
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Vincent Cottin, Arata Azuma, Ganesh Raghu, Wibke Stansen, Susanne Stowasser, Rozsa Schlenker-Herceg, Martin Kolb. Therapeutic effects of nintedanib are not influenced by emphysema in the INPULSIS trials. Eur Respir J, 53 (4) 1801655; 10.1183/13993003.01655-2018
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations
Evidence-based eHealth for COPD
Related content which might interest you:
Recent clinical treatment trials in IPF that focus on pirfenidone and nintedanib
Source: International Congress 2014 – Ceremony for the ERS Idiopathic Pulmonary Fibrosis Research Award 2014 - Hot Topic: "Understanding and treating idiopathic pulmonary fibrosis (IPF) in the 21st century"
Year: 2014
Placebo effects in pharmaceutical clinical trials in bronchiectasis: an EMBARC study
Source: Virtual Congress 2020 – New investigations of bronchiectasis and non-tuberculous mycobacteria
Year: 2020
Heterogeneity of treatment response in bronchiectasis clinical trials
Source: Virtual Congress 2020 – New investigations of bronchiectasis and non-tuberculous mycobacteria
Year: 2020
Changes in biomarkers with nintedanib plus sildenafil in subjects with IPF by presence of emphysema in the INSTAGE trial
Source: Virtual Congress 2020 – Promising biomarkers for idiopathic interstitial pneumonia
Year: 2020
Efficacy of combined therapy with pirfenidone and inhaled N-acetylcysteine for idiopathic pulmonary fibrosis: a randomized controlled phase 3 trial
Source: International Congress 2018 – Management of idiopathic interstitial pneumonias: established and new treatments
Year: 2018
A double blind placebo controlled study to assess the effect of roflumilast in addition to LABA/LAMA/ICS treatment in COPD patients using novel biomarkers
Source: International Congress 2014 – Clinical trials of drugs for respiratory diseases
Year: 2014
Clinical effectiveness of MDI-HFA-Modulite budesonide in the treatment of asthma – meta-analysis of randomised controlled trials
Source: Eur Respir J 2006; 28: Suppl. 50, 315s
Year: 2006
Effects of Roflumilast on subclinical atherosclerosis in COPD - a randomized controlled trial
Source: International Congress 2017 – Extrapulmonary comorbidities in COPD
Year: 2017
Tiotropium reduces the risk of exacerbations irrespective of previous use of inhaled anticholinergics in placebo-controlled clinical trials
Source: Annual Congress 2008 - Pathogenesis and treatment of asthma and COPD
Year: 2008
Effects of combined therapy with nebulized b
2
-agonist and anticholinergic in severe exacerbation of chronic obstructive pulmonary disease. Randomized controlled trial
Source: Eur Respir J 2007; 30: Suppl. 51, 611s
Year: 2007
Efficacy and safety of combined use of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis
Source: Virtual Congress 2021 – News in treatment and diagnosis of idiopathic interstitial pneumonia
Year: 2021
Clinical effectiveness of MDI-HFA-Modulite beclomethasone in the treatment of asthma – meta-analysis of randomized controlled trials
Source: Eur Respir J 2006; 28: Suppl. 50, 315s
Year: 2006
The effect of low-dose corticosteroids and theophylline on the risk of acute exacerbations of COPD: the TASCS randomised controlled trial
Source: Eur Respir J, 57 (6) 2003338; 10.1183/13993003.03338-2020
Year: 2021
Measuring bronchodilation in COPD clinical trials
Source: Eur Respir J 2004; 24: Suppl. 48, 122s
Year: 2004
Exacerbation action plans for patients with COPD and comorbidities: a randomised controlled trial
Source: Eur Respir J, 54 (5) 1802134; 10.1183/13993003.02134-2018
Year: 2019
Safety of formoterol in asthma clinical trials
Source: Annual Congress 2012 - Asthma treatment: efficacy and safety
Year: 2012
Premature discontinuation of patients: a potential bias in COPD clinical trials
Source: Eur Respir J 2007; 30: 898-906
Year: 2007
Lower incidence of asthma exacerbations with F
E
NO-guided anti-inflammatory treatment: A randomised controlled trial
Source: Annual Congress 2012 - Effectiveness of respiratory disease management in primary care
Year: 2012
A randomised controlled trial to investigate the optimal dose and effect of salbutamol for the treatment of acute exacerbations of COPD
Source: Eur Respir J 2002; 20: Suppl. 38, 244s
Year: 2002
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept